Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing

18 de julio de 2026 actualizado por: Edge+Ease

This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy adults aged 18-65 years over 12 weeks of daily use.

Participants will take the Edge+Ease PM product (one serving of powder mixed in approximately 150-250 mL water) in the evening approximately 60-90 minutes before bedtime, and the Edge+Ease AM product (two capsules) in the morning with food. All study activities are conducted remotely via the Citruslabs platform. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will wear a Fitbit continuously beginning 7 days before product use through the end of the 12-week intervention period to provide objective sleep data.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

35

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Descripción

Inclusion Criteria:

  • Male and female adults aged 18 to 65 years.
  • Self-reports difficulty falling asleep, staying asleep, or having poor sleep quality overall, in the last 4 weeks.
  • Self-reports seeking support in at least one of the following domains: Difficulty switching off, perceived stress load, mental overload, next-day mental fatigue, reduced mental clarity or reduced cognitive readiness.
  • Generally healthy.
  • Willing and able to take the PM product (one serving mixed in water) in the evening and the AM product (two capsules with food) in the morning daily for 12 weeks.
  • Willing to maintain current diet, exercise, caffeine, alcohol, and sleep routines for the duration of the study.
  • Willing to wear a Fitbit continuously during the trial, and for 7 days prior to starting the test product.
  • Resides in the United States.

Exclusion Criteria:

  • Known allergy or hypersensitivity to any ingredient in the test product.
  • Currently pregnant, breastfeeding, or trying to conceive, or will be during the study period.
  • Currently undergoing treatment for cancer, or have had a serious illness requiring hospitalization in the last 3 months.
  • Diagnosed severe psychiatric disorder (e.g., bipolar disorder, schizophrenia, major depressive disorder requiring active treatment adjustment) that, in the judgment of the Investigator, would compromise participation or interpretation of results.
  • Diagnosed inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or other significant gastrointestinal condition requiring active management.
  • Current use of prescription antidepressants/anxiolytics, or other prescription neurologically-active medications that have been initiated or had a dose change within the past 90 days.
  • Current use of prescription sleep medications.
  • Regular use (i.e. more than once per week) of melatonin, sedating antihistamines, CBD/THC used for sleep, valerian, ashwagandha, or other sleep-targeted supplements.
  • Initiation of a new dietary supplement targeted at sleep, mood, cognition, or digestion within the 30 days prior to enrollment, or planning to start such a supplement during the study.
  • Heavy drinkers, defined as more than 8 alcoholic drinks per week for women and more than 15 alcoholic drinks per week for men.
  • Currently taking thyroid medication.
  • Currently testing, or plan to in the next 12 weeks, a product for another research study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Edge+ease PM Arm
All enrolled participants receive the Edge+Ease PM+AM system daily for 12 weeks. The PM product (powder) is taken as one serving mixed in approximately 150-250 mL water, around 60-90 minutes before intended bedtime, ideally after dinner.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in Fitbit-measured sleep quality score
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in Fitbit sleep quality score from baseline, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in Fitbit-measured time asleep
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in total time asleep from baseline, measured via Fitbit, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in Fitbit-measured time awake
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in time awake from baseline, measured via Fitbit, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in Fitbit-measured deep sleep
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in deep sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in Fitbit-measured REM sleep
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in REM sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in Fitbit-measured light sleep
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in light sleep duration from baseline, measured via Fitbit, based on the average of three days per time point
Baseline, Week 4, Week 8, and Week 12
Change in self-reported perceived sleep quality
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in perceived sleep quality assessed via questionnaire including the validated Sleep Quality Scale
Baseline, Week 4, Week 8, and Week 12
Change in self-reported sleep satisfaction
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in sleep satisfaction assessed via questionnaire including the validated Sleep Quality Scale
Baseline, Week 4, Week 8, and Week 12
Change in self-reported waking refreshed
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported waking refreshed assessed via questionnaire including the validated Sleep Quality Scale
Baseline, Week 4, Week 8, and Week 12
Change in self-reported morning readiness
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported morning readiness assessed via questionnaire including the validated Sleep Quality Scale
Baseline, Week 4, Week 8, and Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in self-reported mood
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported mood assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported calm
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported calm assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported evening wind-down
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported evening wind-down assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported emotional steadiness
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported emotional steadiness assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported irritability
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported irritability assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported mental clarity
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported mental clarity assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported focus
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported focus assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Change in self-reported digestive comfort
Periodo de tiempo: Baseline, Week 4, Week 8, and Week 12
Mean change in self-reported digestive comfort assessed via questionnaire administered through the study platform
Baseline, Week 4, Week 8, and Week 12
Participant perception of product effect on sleep quality
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on sleep quality assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on sleep satisfaction
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on sleep satisfaction assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on waking refreshed
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on waking refreshed assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on morning readiness
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on morning readiness assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on mood
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on mood assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on calmness
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on calmness assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on evening wind-down
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on evening wind-down assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on task initiation
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on task initiation assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on mental clarity
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on mental clarity assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on focus
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on focus assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on digestive comfort
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on digestive comfort assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on gut health
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on gut health assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Participant perception of product effect on overall wellness
Periodo de tiempo: Week 4, Week 8, and Week 12
Participant-reported perception of product effects on overall wellness assessed via questionnaire administered through the study platform
Week 4, Week 8, and Week 12
Incidence of adverse events
Periodo de tiempo: Throughout study (up to 12 weeks)
Number and percentage of participants experiencing adverse events, characterized by severity and relationship to study product, assessed via self-report questionnaire and investigator review
Throughout study (up to 12 weeks)
Severity of adverse events
Periodo de tiempo: Throughout study (up to 12 weeks)
Severity rating (mild, moderate, severe) of adverse events assessed via self-report questionnaire and investigator review
Throughout study (up to 12 weeks)
Participant discontinuations due to adverse events
Periodo de tiempo: Throughout study (up to 12 weeks)
Number of participants who discontinue the study intervention due to adverse events
Throughout study (up to 12 weeks)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de agosto de 2026

Finalización primaria (Estimado)

1 de diciembre de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

18 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de julio de 2026

Publicado por primera vez (Actual)

23 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir